Cytodyn Inc (CYDY)

[BlackDoggie]

Hi Pearsby, I think we may have miscommunicated. GILD didn't buy the drug, they bought the priority review voucher (PRV). Sarepta sold the voucher (which is legal for some reason) because the drug for which they were granted the voucher (Exo 51) was actually approved before the voucher was used. The voucher allows Gilead to submit a different drug for approval under priority review. For example, review the table about halfway down this article:

http://camargopharma.com/2016/07/tropical-rare-pediatric-disease-priority-review-vouchers-update-use-505b2-pathway/

You'll see that Rare Pediatric PRV have been bought and used for high cholesterol drugs, Type 2 diabetes treatments, etc. I'm not even sure now that GILD has to use it for a Rare Pediatric Disease. It just allows them to bring a drug to market more quickly. Which looks perfect for a case like PRO 140 which still has some runway to market, but where CYDY may be looking to sell. PRV would lower GILD's cost of bringing a late-stage drug to market, and get it there faster.

Or maybe I'm misunderstanding. Thoughts?